Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefradine is a first-generation, semi-synthetic cephalosporin antibiotic belonging to the beta-lactam class. It is used in the treatment of a variety of bacterial infections including those of the respiratory tract (such as tonsillitis, pharyngitis, and pneumonia), urinary tract (including prostatitis), skin and soft tissues, ear (otitis media), and sinusitis. Cefradine acts by binding to penicillin-binding proteins inside bacterial cell walls, inhibiting the final stage of peptidoglycan synthesis required for cell wall integrity. This disruption leads to cell lysis and death via activation of autolytic enzymes within bacteria[1][2][3][7][8]. Its spectrum of activity is similar to that of cefalexin. Cefradine is not approved by the FDA for use in the United States but has been marketed under various brand names elsewhere.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefradine.